Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warning

Neurology

Volumn 67, Issue 4, 2006, Pages 564-566

  Friedman, Joseph H ^a  

^a NeuroHealth Parkinson's Disease and Movement Disorders Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGING; CLINICAL TRIAL; DISEASE EXACERBATION; FOOD AND DRUG ADMINISTRATION; HUMAN; META ANALYSIS; METABOLIC SYNDROME X; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SEDATION; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW;

ANTIPSYCHOTIC AGENTS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DRUG APPROVAL; DRUG LABELING; EVIDENCE-BASED MEDICINE; HUMANS; PARKINSON DISEASE; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 33747631017     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000229933.91780.67     Document Type: Review

References (49)

1. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
2. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000;15:201-211.
3. Moskovitz C, Moses H 3rd, Klawans HL. Levodopa induced psychosis: a kindling phenomenon. Am J Psychiatry 1978;135:669-675.
4. Parkinson Study Group. Low dose clozapine for the treatment of drug induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-763.
5. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomized placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689-695.
6. Friedman JH. The management of the dopamine psychoses in PD. Clin Neuropharmacol 1991;14:289-295.
7. de Francisco CP, Portillio RG. Pharmacopsychiatry and iatrogenic parkinsonism. Adv Exp Med Biol 1977;90:191-196.
8. Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology 2000;148:3-15.
9. Committee of Safety of Medicines. Atypical antipsychotic drugs and stroke. http:/medicines.mhra.gov.uk/ourwork/monitorsafequalmed/messages/ risperidone-clinicaltrialdata final.pdf. Accessed May 13, 2004.
10. Wooltorton E. Risperidone: increased rate of cerebrovascular events in dementia trials. Can Med Assoc J 2002;167:1269-1270.
11. Wooltorton E. Olanzapine: increased incidence of cerebrovascular events in dementia trials. Can Med Assoc J 2004;170:1395.
12. Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs 2005;19:91-103.
13. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. Br Med J 2005;330:445.
14. Liperoti R, Mor V, Lapane KL, et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003;64:1106-1112.
15. Wallaschofski H, Donne M, Eigenthaler M, et al. PRL as a novel potential cofactor for platelet aggregation. J Clin Endocrinol Metab 2001;86:5912-5919.
16. Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005;66:1090-1096.
17. Smith DA, Beier MT. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc 2004;5:129-132.
18. Hagg S, Spigse O. Antipsychotic-induced venous thromboembolism. CNS Drugs 2002;16:765-776.
19. Yang CH, Tsai SJ, Hwang JP. The efficacy and safety of quetiapine for treatment of geriatric psychosis. J Psychopharmacol 2005;19:666-669.
20. De Deyn PP, Katz IR, Brodaty H, et al. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo controlled double blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg 2005;107:497-508.
21. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:115-126.
22. Ballard C, Cream J. Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cost? Int Psychogeriatr 2005;17:4-12.
23. Deberdt WG, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry 2005;13:722-730.
24. Katz IR, Jeste DV, Mintzer JE, Clyde C, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial: Risperidone Study Group. J Clin Psychiatry 1999;60:107-115.
25. Ballard C, Margall-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. Br Med J 2005;330:874-879.
26. Breder C, Swanink R, Marcus R, et al. Dose-ranging study of aripiprazole in patients with Alzheimer's dementia. Presented at 9th International conference on Alzheimer's Disease and Related Disorders, July 17 to 22, 2004, Philadelphia, PA.
27. Street JS, Tollefson GD, Tohen M, et al. Olanzapine for psychotic conditions in the elderly. Psychiatr Ann 2000;30:191-196.
28. Cavazzoni P, Young CA, Polzer J, et al. Incidence of cerebrovascular adverse events and mortality during antipsychotic clinical trials of elderly patient with dementia. Paper presented at 44th annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, June 1 to 4, 2004, Phoenix, AZ.
29. Expert Consensus on Management of Behavioral Symptoms in the Elderly. Postgrad Med 2004;suppl 1.
30. Expert Consensus Guideline Series Using Antipsychotic Agents in Older Patients. J Clin Psychiatry 2004;65(suppl 2).
31. Am Geriatric Society and American Association for Geriatric Psychiatry Consensus Statement on improving the quality of mental health care in US nursing homes: management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc 2003;51:1287-1298.
32. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of random placebo controlled trials. JAMA 2005;294:1934-1943.
33. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional versus atypical antipsychotic medications. N Engl J Med 2005;353:2335-2341.
34. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Safety 2005;26:643-659.
35. Fernandez HH, Friedman JH, Lansung MC, et al. Diabetes mellitus among Parkinson patients treated chronically with clozapine. Parkinsonism 2004;10:439-441.
36. Morgante L, Epifano A, Spina E, et al. Quetiapine and clozapine in Parkinson's disease patients with dopaminergic psychosis. Clin Neuropharmacol 2004;27:153-156.
37. Mancini F, Tassorelli C, Martignoni E, et al. Long-term evaluation of the effects of quetiapine on hallucinations, delusions and motor function in advanced Parkinson's disease. Clin Neuropharmacol 2004;27:33-37.
38. Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004;19:29-35.
39. Ondo WG, Tintner R, Vuong KD, et al. Double-blind, placebo controlled unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-963.
40. Rabey JM, Prokhorov T, Miniovich A, et al. The effect of quetiapine in Parkinson's disease psychotic patients: a double blind study of three months duration. Mov Disord 2005;20(suppl 10):S46.
41. Gomez-Esteban K, Zarranz JJ, Velasco F, et al. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol 2005;28:11-14.
42. Oeschsner M, Korchounov A. Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease. Psychopharmacology 2005;20:203-205.
43. Michelli F, Taubenslag N, Gatto E, Scorticati MC. Ziprasidone and psychosis in Parkinson disease. Clin Neuropharmacol 2005;28:254.
44. Bilal L, Tsai C, Gasper JJ, Ndlela JC. Parkinsonism with intramuscular ziprasidone. Am J Psychiatry 2005;162:2392-2393.
45. Layton D, Harris S, Wilton LV, Shakir SA. Comparison of incidence rates of cerebrovascular accidents and transient ischemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England, including patients with dementia. J Psychopharmacol 2005;19:473-482.
46. Carson S, McDonagh MS, Peterson K. A systematic review of the efficacy and safety of atypical antipsychotic in patients with psychological and behavioral symptoms of dementia. J Am Geriatr Soc 2006;5:354-361.
47. Kozma CM, Engelhart LM, Long S, et al. Absence of increased relative stroke risk in elderly dementia patients treated with risperidone versus other antipsychotic. 2003 meeting of the Intl College of Geriatric Psychoneuropharmacology. www.icgp.org/ICGP_2003_program_Book.pdf.
48. Nasrallah HA, White T, Nasrallat AT. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data. Am J Geriatr Psychiatry 2004;12:437-439.
49. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60:1756-1761.